HOME >> BIOLOGY >> NEWS
Pittsburgh researchers engineer and successfully test SARS corona vaccine in animal model

PITTSBURGH, Dec. 4 -- Research by scientists at the University of Pittsburgh School of Medicine and the Graduate School of Public Health (GSPH) in collaboration with colleagues at the Centers for Disease Control and Prevention (CDC) in Atlanta has shown that an adenoviral-based vaccine can induce SARS-coronavirus (SARS-CoV)-specific T-cell and virus-neutralizing antibody responses.

The study, which represents the first published work on the development of a SARS vaccine and comes only a few months after the SARS coronavirus was identified and its genome was sequenced, is reported in a fast track research letter in the Dec. 6 issue of The Lancet.

"It is our hope that this research will lead to a protective vaccine against SARS," stated project leader Andrea Gambotto, M.D., from the departments of surgery and medicine, division of infectious diseases and the Molecular Medicine Institute (MMI) at the University of Pittsburgh School of Medicine.

In the study, researchers immunized six rhesus macaques intramuscularly with a combination of three SARS-CoV vectors. Two additional macaques were immunized with the same amount of empty adenoviral vector and served as controls. After 28 days, the animals received a second vaccination. Six weeks after vaccination, T-cells and antibodies against SARS were detected in all six of the immunized animals, but not in either of the control animals. The intensity of the response varied among animals but was generally largest after the booster vaccination, according to the Pittsburgh researchers. Serum samples from the vaccinated animals, but not from the controls, showed strong neutralizing capacity against SARS-CoV.

"From a scientific perspective, several points are important. We obtained the recombinant vaccine by engineering a common cold virus to express the SARS coronavirus antigens. This is a successful strategy that we are exploring for other infectious diseases such as HIV," said Dr. Gambott
'"/>

Contact: Frank Raczkiewicz
RaczkiewiczFA@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
4-Dec-2003


Page: 1 2 3

Related biology news :

1. University of Pittsburgh receives $10 million grant for head and neck cancer
2. University of Pittsburgh medical center among first to implant heart assist device
3. University of Pittsburgh receives NIH funding to develop heart assist device for infants
4. Pittsburgh NMR Center for Biomedical Research at Carnegie Mellon
5. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
6. Protein biomarkers accurately and quickly diagnose ALS, find Pittsburgh researchers
7. University of Pittsburgh scientist honored for major accomplishment in cancer research
8. Worlds largest scientific society to hold regional meeting in Pittsburgh
9. University of Pittsburgh named cooperative research center for muscular dystrophy
10. Infectious disease study findings presented by University of Pittsburgh scientists
11. University of Pittsburgh study links gynecological complaint to increased risk for herpes

Post Your Comments:
(Date:4/17/2014)... CHAMPAIGN, Ill. A drug under clinical trials to ... of broad-spectrum drugs that act against various bacteria, fungal ... study by University of Illinois chemists and collaborators. , ... the team determined the different ways the drug SQ109 ... tweaked to target other pathogens from yeast to malaria ...
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2New state-of-the-art biotech and nanotech equipment for INRS 2
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
Cached News: